title: What next? Choosing second-line therapy in progressive renal cell carcinoma.
authors.forename: María T
authors.initials: MT
authors.lastname: Bourlon
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Kessler
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000077784:Axitinib; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000556:secondary / Q000601:surgery*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007191:Indazoles / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery*; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D008207:Lymphatic Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D011859:Radiography; D013125:Spinal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D007093:Imidazoles; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib; D000077784:Axitinib